BC Innovations | Oct 12, 2017
Translation in Brief

Opening doors for I-O

A Science Translational Medicine study has flipped the script for tumor lymphangiogenesis by turning VEGF-C , a hallmark of poor prognosis, into a biomarker and a target for successful responses to immunotherapies. Tumors that are surrounded...
BC Innovations | Oct 3, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of VEGF-C could help predict responses to immunotherapies in patients with solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A ( MLANA ; MART1) peptide and the toll-like...
BC Week In Review | Sep 21, 2015
Clinical News

PF-3512676: Phase II data

Researchers at the VU University Medical Center Cancer Center Amsterdam reported data from 52 patients with stage I/II melanoma in a pair of Phase II trials showing that 2 or 8 mg intradermal CpG7909 injected...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...
BC Week In Review | Apr 14, 2014
Clinical News

Astuprotimut-R: Phase III discontinued

GlaxoSmithKline stopped the double-blind, international Phase III MAGRIT trial in 2,312 stage IB, II or IIIA NSCLC patients whose tumors expressed the MAGEA3 gene after a pre-planned independent third-party analysis showed that there was an...
BC Week In Review | Mar 24, 2014
Clinical News

Astuprotimut-R: Phase III data

The double-blind, international Phase III MAGRIT trial in 2,312 stage IB, II or IIIA NSCLC patients whose tumors expressed the MAGEA3 gene showed that intramuscular MAGE-A3 given after surgical removal of a patient's tumors missed...
BC Extra | Mar 20, 2014
Clinical News

GSK's MAGE-A3 misses in Phase IIII NSCLC trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said intramuscular MAGE-A3 missed the co-primary endpoints of improving disease-free survival (DFS) vs. placebo in both the overall population and in patients who did not receive chemotherapy in the Phase III...
BC Week In Review | Sep 9, 2013
Clinical News

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic: Phase III data

The double-blind, international Phase III DERMA trial in 1,345 stage IIIB/C melanoma patients with macroscopic nodal disease whose tumors expressed the MAGEA3 gene showed that intramuscular MAGE-A3 given after surgical removal of a patient's tumors...
BC Extra | Sep 5, 2013
Clinical News

GSK's MAGE-A3 misses in Phase III melanoma trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said intramuscular MAGE-A3 given after surgical removal of a patient's tumors missed the co-primary endpoint of improving disease-free survival (DFS) vs. placebo n the Phase III DERMA trial to treat melanoma-associated...
BC Week In Review | Oct 4, 2010
Clinical News

Bosutinib: Development discontinued

Pfizer Inc. (NYSE:PFE), New York, N.Y.   Product: Bosutinib ( SKI-606 , PF-5208763 ); Celebrex celexcoxib ( YM177 , Celecox ); CP-533536 ( CP-533,536 ); dibotermin alfa ; figitumumab ( CP-751,871 , CP-751871 ); Lyrica pregabalin; PF-21780; PF-299685; PF-3512676 ( CpG7909 ); SU-14813;...
Items per page:
1 - 10 of 44